We are delighted to announce that the University of Bristol Enterprise Fund II, managed by Parkwalk, has invested in Vitamica, a University of Bristol spin-out that aims to exploit a novel approach for determining the susceptibility of bacteria to antibiotics.
Resistance of bacteria to antibiotics is an increasing problem across the world, resulting in poorer healthcare outcomes, higher costs and a reduction in the number of effective drugs.
Research in the School of Physics has demonstrated a highly sensitive and rapid method for differentiating bacterial cells that are resistant to applied antibiotics from those that are rendered inactive by treatment. The technique could be used in human and veterinary healthcare settings to improve decision making on antibiotic selection.
